Starting in 1954 Krka has grown from a laboratory team of nine people into a company with almost 13,000 employees worldwide. We provide therapies for many common diseases and conditions across human and animal health.  Our goal is clear: to provide affordable therapy of the highest quality that supports people and the animals they care for, to have healthier lives.

Krka is now one of the leading generic pharmaceutical companies in the world, and our medicines are used to treat more than 50 million human and animal patients globally every day. Working closely with customers, Krka supplies licensed medicines that deliver effective and consistent performance in clinical practice. 

Today, generic pharmaceuticals are seen as invaluable to widening patient access to medicines, a key element of the global One Health initiative. In human health, the role of generic medicine suppliers is well established and consumers are used to seeing a wide selection of manufacturer brands in the medicines they use. This trend is now also developing in animal health too. A 2023 UK survey commissioned by Krka, highlighted the key benefits the UK vet sector is now recognising that generic medicines can provide. The top three ranked benefits identified by the survey were:

• More affordable medicines for clients

• Higher practice margins

• Greater availability of actives

With over 50 years in developing animal health solutions Krka continues to bring innovation to the category. Our Animal Health Portfolio provides high efficacy pharmaceuticals for both companion and food producing animals covering parasite control, infection management and pain relief.  Key brands for companion animals include Milprazon CHEWABLE® and Prinocate®, for parasite management and Cladaxxa® for infection control.

Our most recent product launch expands the Krka range for pain management care for dogs, a rapidly evolving category. Robexera® (robenacoxib) provides highly targeted treatment of pain and inflammation due to osteoarthritis and soft tissue surgery in dogs.

The product is presented as a flavoured chewable tablet for easier administration by pet owners and for dispensing simplicity. It comes in four strengths with colour coded boxes, perforated blisters and a set of PIL sheets that convert to prescribing envelopes in each pack.

Learn more about Robexera from the Krka Team at BVA Live # B25 on June 6-7th at the NEC. For more information click here

Link for the click here above (https://www.krka.co.uk/products/our-products/animal-health/robexera-20mg/).